PegNeufil SC Injection

✔️ Dosage & Administration of PegNeufil 6mg/0.6ml

• A single subcutaneous injection of 6 mg per chemotherapy cycle for adults.
• Do not administer PegNeufil 14 days before or 24 hours after chemotherapy.
• Inspect the solution for discoloration or particulate matter. Do not use if abnormalities are observed.
• The needle cover contains dry natural rubber (latex); avoid it in individuals with latex allergies.

Pediatric Use:

• Safety and efficacy in children have not been established.

Geriatric Use:

• No significant differences in safety or effectiveness between older adults (65+ years) and younger patients were observed in clinical studies.

Renal Impairment:

• No dosage adjustment is needed in patients with renal dysfunction, including end-stage renal disease.

✔️ Overdose Effects of PegNeufil 6mg/0.6ml

• The maximum safe dosage is not determined.
• Single doses of up to 300 mcg/kg have been administered without serious effects. Observed effects include increased Absolute Neutrophil Count (ANC) and White Blood Cell (WBC) counts.

✔️ Serious Risks:

Splenic Rupture:

• Fatal splenic rupture has been reported. Evaluate for an enlarged spleen or splenic rupture in patients experiencing left upper abdominal or shoulder pain.

Acute Respiratory Distress Syndrome (ARDS):

• This may occur in patients receiving PegNeufil. Monitor for fever, lung infiltrates, or respiratory distress. Discontinue PegNeufil in patients with ARDS.

Serious Allergic Reactions:

• Including anaphylaxis, which may recur after the initial reaction subsides. Permanently discontinue PegNeufil in such cases.

Sickle Cell Crisis:

• Severe and potentially fatal sickle cell crises have occurred in patients with sickle cell disorders receiving Pegfilgrastim or Filgrastim.

✔️ Drug Interactions

• No formal studies have been conducted on drug interactions with PegNeufil.
• Bone-imaging changes: Increased hematopoietic activity due to PegNeufil may transiently affect bone-imaging results. Consider this when interpreting scans.
• Mixing: Do not mix PegNeufil with other medicinal products, especially sodium chloride solutions.

✔️ PegNeufil is contraindicated in patients with:

• A history of severe allergic reactions to Pegfilgrastim or Filgrastim.

✔️ Pregnancy & Lactation

Pregnancy (Category C):

• Animal studies indicate potential harm to the fetus. Use only if the potential benefit outweighs the risk.

Lactation:

• It is not known if PegNeufil is secreted in human milk. Caution is advised when administering to nursing women.

✔️ Storage Conditions

• Store at 2–8°C (refrigerated).
• Do not freeze or shake.
• Protect from light. Keep out of reach of children.